Beyond biologics: Amgen bets new drugs will pay dividend
Amgen executives believe the biotech giant will grow substantially in the next decade, pursuing drugs that treat major melanoma and bone loss.
NEXT ARTICLE →
ValueClick defies its skeptics
← PREVIOUS ARTICLE
Smaller, better, faster: Goleta photonics firm looks for a breakthrough